Market Overview:
The global bendamustine injection market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for better treatment options, and growing awareness about available treatments. Based on type, the global bendamustine injection market is segmented into 25mg injection, 100mg injection, and others. The 100mg injection segment is expected to account for the largest share of the global bendamustine injection market in 2018. This segment is also projected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. This growth can be attributed to its high efficacy and safety profile compared with other types of injections available in this market. Based on application, the global bendamustine injection market is divided into chronic lymphocytic leukemia (CLL), multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), and others. The CLL segment accounted for majority share of the global Bendamustine Injection Market by application in 2017 and it will continue its dominance throughout 2027 owing continuous product launches by key players coupled with rising prevalence rates across major geographies worldwide .
Product Definition:
Bendamustine (Treanda) is a chemotherapy drug used to treat chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma, and Hodgkin's disease. Bendamustine is given by IV infusion over 30 minutes.
25mg Injection:
25mg Injection is used for the treatment of chronic myelogenous leukemia, a type of cancer that affects the blood and bone marrow. Chronic myelogenous leukemia (CML) is also known as multiple myeloma or clonal plasma cell cancer. It is one of the most common forms of blood cancer in western countries.
100mg Injection:
Bendamustine Injection is a medication used for the treatment of multiple myeloma and lymphomas. It works by damaging the cells that make up the immune system, which in turn reduces inflammation and pain caused by bone cancer or arthritis.
Application Insights:
The chronic lymphocytic leukemia segment dominated the global bendamustine injection market in 2017 and is expected to witness the fastest growth over the forecast period. Chronic lymphocytic leukemia (CLL) is a type of blood cancer which affects mostly elderly people and people who have received a stem cell transplant. The disease develops after an individual has been exposed to certain viruses, most notably Epstein-Barr virus, for many years. According to data published by WHO, around 100000 individuals are diagnosed with CLL every year globally while around 25000 die due to this disease annually. Bendamustine injection is approved by FDA for treatment of CLL thus represents a potential lucrative revenue stream generating opportunity for key players in North America and Europe regions.
The multiple myeloma segment held a significant share in 2017 owing to high incidence rates of this cancer across various regions coupled with increasing awareness about its early diagnosis & treatment among patients as well as healthcare professionals globally.
Regional Analysis:
Asia Pacific dominated the global market in 2017. This can be attributed to increasing healthcare expenditure, rising awareness about cancer treatment options, and availability of effective treatment facilities in this region. In addition, high prevalence of blood cancers such as leukemia and lymphoma is also expected to drive the regional market during the forecast period. For instance, according to data published by Globocan estimates that around 6 lakh people were diagnosed with CLL globally.
In addition, increasing initiatives undertaken by regulatory bodies for improving access & affordability for bendamustine are further anticipated to propel growth over the forecast period. For instance; Medicines and Healthcare Products Regulatory Agency (MHRA) has reduced price of Bendamustine from USD X per vial down to USD X per vial through its Special Programme Funded Scheme (SPFS).
Growth Factors:
- Increasing incidence of lymphoma and leukemia across the globe is expected to drive the demand for Bendamustine Injection over the forecast period.
- The increasing number of clinical trials for Bendamustine Injection is anticipated to propel market growth during the forecast period.
- Rising geriatric population base is likely to fuel market growth as this population segment is more susceptible to lymphoma and leukemia, which are key indications for Bendamustine Injection therapy.
- Availability of generic versions of Bendamustine Injection is projected to reduce treatment costs, thereby driving market uptake over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Bendamustine Injection Market Research Report
By Type
25mg Injection, 100mg Injection, Others
By Application
Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma, Others
By Companies
Teva, Eisai, Eagle Pharmaceuticals, MundiPharma, Mylan, Natco Pharma, Emcure, Miracalus Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
200
Number of Tables & Figures
140
Customization Available
Yes, the report can be customized as per your need.
Global Bendamustine Injection Market Report Segments:
The global Bendamustine Injection market is segmented on the basis of:
Types
25mg Injection, 100mg Injection, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Teva
- Eisai
- Eagle Pharmaceuticals
- MundiPharma
- Mylan
- Natco Pharma
- Emcure
- Miracalus Pharma
Highlights of The Bendamustine Injection Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 25mg Injection
- 100mg Injection
- Others
- By Application:
- Chronic Lymphocytic Leukemia
- Multiple Myeloma
- Non-Hodgkin's Lymphoma
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Bendamustine Injection Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Bendamustine is a chemotherapy drug that is used to treat various types of cancer. It works by killing cancer cells.
Some of the key players operating in the bendamustine injection market are Teva, Eisai, Eagle Pharmaceuticals, MundiPharma, Mylan, Natco Pharma, Emcure, Miracalus Pharma.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Bendamustine Injection Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Bendamustine Injection Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Bendamustine Injection Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Bendamustine Injection Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Bendamustine Injection Market Size & Forecast, 2018-2028
4.5.1 Bendamustine Injection Market Size and Y-o-Y Growth
4.5.2 Bendamustine Injection Market Absolute $ Opportunity
Chapter 5 Global Bendamustine Injection Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Bendamustine Injection Market Size Forecast by Type
5.2.1 25mg Injection
5.2.2 100mg Injection
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Bendamustine Injection Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Bendamustine Injection Market Size Forecast by Applications
6.2.1 Chronic Lymphocytic Leukemia
6.2.2 Multiple Myeloma
6.2.3 Non-Hodgkin's Lymphoma
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Bendamustine Injection Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Bendamustine Injection Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Bendamustine Injection Analysis and Forecast
9.1 Introduction
9.2 North America Bendamustine Injection Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Bendamustine Injection Market Size Forecast by Type
9.6.1 25mg Injection
9.6.2 100mg Injection
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Bendamustine Injection Market Size Forecast by Applications
9.10.1 Chronic Lymphocytic Leukemia
9.10.2 Multiple Myeloma
9.10.3 Non-Hodgkin's Lymphoma
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Bendamustine Injection Analysis and Forecast
10.1 Introduction
10.2 Europe Bendamustine Injection Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Bendamustine Injection Market Size Forecast by Type
10.6.1 25mg Injection
10.6.2 100mg Injection
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Bendamustine Injection Market Size Forecast by Applications
10.10.1 Chronic Lymphocytic Leukemia
10.10.2 Multiple Myeloma
10.10.3 Non-Hodgkin's Lymphoma
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Bendamustine Injection Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Bendamustine Injection Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Bendamustine Injection Market Size Forecast by Type
11.6.1 25mg Injection
11.6.2 100mg Injection
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Bendamustine Injection Market Size Forecast by Applications
11.10.1 Chronic Lymphocytic Leukemia
11.10.2 Multiple Myeloma
11.10.3 Non-Hodgkin's Lymphoma
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Bendamustine Injection Analysis and Forecast
12.1 Introduction
12.2 Latin America Bendamustine Injection Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Bendamustine Injection Market Size Forecast by Type
12.6.1 25mg Injection
12.6.2 100mg Injection
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Bendamustine Injection Market Size Forecast by Applications
12.10.1 Chronic Lymphocytic Leukemia
12.10.2 Multiple Myeloma
12.10.3 Non-Hodgkin's Lymphoma
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Bendamustine Injection Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Bendamustine Injection Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Bendamustine Injection Market Size Forecast by Type
13.6.1 25mg Injection
13.6.2 100mg Injection
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Bendamustine Injection Market Size Forecast by Applications
13.10.1 Chronic Lymphocytic Leukemia
13.10.2 Multiple Myeloma
13.10.3 Non-Hodgkin's Lymphoma
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Bendamustine Injection Market: Competitive Dashboard
14.2 Global Bendamustine Injection Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Teva
14.3.2 Eisai
14.3.3 Eagle Pharmaceuticals
14.3.4 MundiPharma
14.3.5 Mylan
14.3.6 Natco Pharma
14.3.7 Emcure
14.3.8 Miracalus Pharma
